Cargando…
FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin
Docetaxel is commonly used as an effective chemotherapeutic drug for gastric cancer patients recently. With the increasing emergence of docetaxel resistance nowadays, identification of suitable biomarkers for predicting chemosensitivity to docetaxel may be a key role for improving therapeutic effect...
Autores principales: | Li, Xiaoxiao, Yao, Ruyong, Yue, Lu, Qiu, Wensheng, Qi, Weiwei, Liu, Shihai, Yao, Yasai, Liang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119387/ https://www.ncbi.nlm.nih.gov/pubmed/24628949 http://dx.doi.org/10.1111/jcmm.12216 |
Ejemplares similares
-
Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel
por: Li, Xiaoxiao, et al.
Publicado: (2013) -
NHE1 Mediates 5-Fu Resistance in Gastric Cancer via STAT3 Signaling Pathway
por: Sun, Zhenni, et al.
Publicado: (2020) -
MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1
por: Yao, YaSai, et al.
Publicado: (2015) -
Impact of NPM, TFF3 and TACC1 on the Prognosis of Patients with Primary Gastric Cancer
por: Ding, Aiping, et al.
Publicado: (2013) -
SEPTIN2 and STATHMIN Regulate CD99-Mediated Cellular Differentiation in Hodgkin's Lymphoma
por: Jian, Wenjing, et al.
Publicado: (2015)